PNC Financial Services Group
GLUE icon

PNC Financial Services Group’s Monte Rosa Therapeutics GLUE Stock Holding History

PNC Financial Services Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.31K Sell
445
-12
-3% -$206 ﹤0.01% 4485
2026
Q2 		$11.1K Hold
457
– – ﹤0.01% 4037
2026
Q1 		$7.52K Hold
457
– – ﹤0.01% 4077
2025
Q4 		$7.17K Hold
457
– – ﹤0.01% 4090
2025
Q3 		$3.39K Buy
457
+340
+291% +$1.8K ﹤0.01% 4347
2025
Q2 		$528 Buy
117
+51
+77% +$227 ﹤0.01% 4679
2025
Q1 		$306 Buy
66
+38
+136% +$233 ﹤0.01% 4723
2024
Q4 		$194 Hold
28
– – ﹤0.01% 4654
2024
Q3 		$148 Hold
28
– – ﹤0.01% 4701
2024
Q2 		$105 Buy
+28
New +$143 ﹤0.01% 4714

Other funds holding GLUE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Versant Venture Management
Versant Venture Management San Francisco, California $109M AUM 43.78% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

PNC Financial Services Group's GLUE Position: Q3 2026 in Review

PNC Financial Services Group reduced its Monte Rosa Therapeutics (GLUE) stake by 2.6% in Q3 2026, selling an estimated $206 and leaving 445 shares worth $5.31K. The position accounts for ﹤0.01% of the portfolio, ranked #4485.

PNC Financial Services Group first reported a position in GLUE in Q2 2024 and has held it in 10 quarters since. The position peaked at $11.1K in Q2 2026. 124 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • PNC Financial Services Group held 445 shares of Monte Rosa Therapeutics worth $5.31K as of Q3 2026.
  • PNC Financial Services Group sold 12 Monte Rosa Therapeutics shares in Q3 2026, an estimated $206.
  • Monte Rosa Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4485 holding.
  • PNC Financial Services Group first reported a position in Monte Rosa Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • PNC Financial Services Group's Monte Rosa Therapeutics position peaked at $11.1K in Q2 2026.
  • 124 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.